These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2499702)

  • 1. Methotrexate clearance and clinical toxicity in osteosarcoma following high-dose methotrexate therapy.
    Iqbal MP; Khursheed M; Mahboobali N
    J Pak Med Assoc; 1989 Feb; 39(2):38-42. PubMed ID: 2499702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose methotrexate for osteosarcoma: toxicity and clinical results.
    Breithaupt H; Küenzlen E
    Oncology; 1983; 40(2):85-9. PubMed ID: 6600827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose methotrexate with a safe rescue program.
    Decker DA; Edmonson JH; Gilchrist GS; Kovach JS; Offord JR; Taylor WF
    Oncology; 1981; 38(5):262-4. PubMed ID: 6973732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.
    Hegyi M; Gulácsi A; Cságoly E; Csordás K; Eipel OT; Erdélyi DJ; Müller J; Nemes K; Lautner-Csorba O; Kovács GT
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1697-702. PubMed ID: 22652833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
    Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
    Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A device for rapid elevation of plasma methotrexate (MTX) concentration and its maintenance in high-dose MTX therapy].
    Miyauchi Y; Mii Y; Morishita T; Miura S; Honoki K; Aoki M; Kido A; Tamai S; Hino M; Nomura Y; Nakanishi E
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):595-9. PubMed ID: 8678518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum methotrexate determination by microbiological assay in patients receiving high-dosage methotrexate (author's transl)].
    Krisch K; Kotz D; Mehta BM
    Wien Klin Wochenschr; 1977 Jul; 89(14):479-81. PubMed ID: 268729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma phenylalanine: tyrosine ratios during high-dose methotrexate-citrovorum "rescue".
    Hilton MA; Patel CC; Bertolone SJ; Kmetz DR; Clark LW
    Med Pediatr Oncol; 1982; 10(4):389-95. PubMed ID: 6981054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma.
    Delepine N; Delepine G; Cornille H; Brion F; Arnaud P; Desbois JC
    Anticancer Res; 1995; 15(2):489-94. PubMed ID: 7763028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
    Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of methotrexate by the ligand-binding assay after "high-dose" therapy for osteosarcoma.
    Roberts D; Kidd W; Pratt CB; Peck C; Grinnel J
    Cancer; 1979 Sep; 44(3):881-90. PubMed ID: 314328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Potential marker of the pharmacodynamic effect of high doses of methotrexate--homocysteine].
    Strizhevskaya AM; Senzhapova ER; Dzamraev AZ; Baykova VN
    Patol Fiziol Eksp Ter; 2014; (2):40-4. PubMed ID: 25318162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
    Perez C; Wang YM; Sutow WW; Herson J
    Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
    Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
    Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose leucovorin as sole therapy for methotrexate toxicity.
    Flombaum CD; Meyers PA
    J Clin Oncol; 1999 May; 17(5):1589-94. PubMed ID: 10334548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate megadosage followed by folate rescue. I. A study in clearance patterns.
    Salasoo S; Irving MG; Lam-Po0Tang R; O'Gorman-Hughes D; Freedman A
    Med J Aust; 1976 May; 1(21):777-9. PubMed ID: 1085404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of severe side effects of high-dose methotrexate in osteosarcoma].
    Umeda T; Takada N; Hodaka E; Endoh F; Ishii T
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):285-94. PubMed ID: 6582805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma.
    Young EP; Cheng WS; Bernhardt MB; Wang LL; Rainusso N; Foster JH
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28123. PubMed ID: 31867853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
    Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
    Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.